Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Susan, Hershenson"'
Autor:
Joshua Brown, Tamra Goodrow, Dan Hartman, Justin L. Hay, Kevin Hershberger, Susan Hershenson, Douglas McNair, Bethany Matthews, Mark A. Milad, Stephan Schmidt, Kirsten M Vogelsong, Ping Zhao
Publikováno v:
Contraception: X, Vol 4, Iss , Pp 100072- (2022)
Developing new long-acting products of well-characterized contraceptive drugs is one way to address some of the reasons for unmet need for modern methods of family planning among women in low- and middle-income countries. Development and approval of
Externí odkaz:
https://doaj.org/article/a9fca8cf75c04490838f743ef8553fe5
Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings
Publikováno v:
Pharmaceutics, Vol 11, Iss 10, p 518 (2019)
Despite advances in regulations and initiatives to increase pediatric medicine development, there is still an unmet need for age-appropriate medicines for children. The availability of pediatric formulations is particularly lacking in resource poor a
Externí odkaz:
https://doaj.org/article/5114d1ebe1ab4ba1bf018e86b197f0f2
Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings
Publikováno v:
Pharmaceutics, Vol 11, Iss 10, p 518 (2019)
Pharmaceutics
Pharmaceutics
Despite advances in regulations and initiatives to increase pediatric medicine development, there is still an unmet need for age-appropriate medicines for children. The availability of pediatric formulations is particularly lacking in resource poor a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91293177e31df5220ec9f62b5de8c6b2
https://www.mdpi.com/1999-4923/11/10/518
https://www.mdpi.com/1999-4923/11/10/518
Autor:
Savannah J, McFeely, Jingjing, Yu, Ping, Zhao, Susan, Hershenson, Steven, Kern, Isabelle, Ragueneau-Majlessi, Dan, Hartman
Publikováno v:
Clinical Pharmacology and Therapeutics
Despite recent advances in recognizing and reducing the risk of drug–drug interactions (DDIs) in developed countries, there are still significant challenges in managing DDIs in low‐income countries (LICs) worldwide. In the treatment of major infe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::aaf79179d448c49904ee7aabfd4e1fdb
https://pubmed.ncbi.nlm.nih.gov/30771252
https://pubmed.ncbi.nlm.nih.gov/30771252
Autor:
John F. Carpenter, Rodney J. Y. Ho, Susan Hershenson, David B. Volkin, Gerhard Winter, Susumu Uchiyama
Publikováno v:
Journal of Pharmaceutical Sciences. 104:290-300
Recombinant biological products have revolutionized modern medicine by providing both remarkably effective vaccines to prevent disease and therapeutic drugs to treat a wide variety of unmet medical needs. Since the early 1980s, dozens of new therapeu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7416b31da3cd075517d4a6969c343051
https://doi.org/10.1002/jps.24285
https://doi.org/10.1002/jps.24285
This volume explores the application of Quality by Design (QbD) to biopharmaceutical drug product development. Twenty-eight comprehensive chapters cover dosage forms, liquid and lyophilized drug products. The introductory chapters of this book define
Autor:
Karthik Nagapudi, Gayathri Ratnaswamy, Hong Lin, Wenjin Cao, Deirdre Murphy Piedmonte, Priti Baker, Susan Hershenson, Alison Hair, Lejla Brych
Publikováno v:
Journal of pharmaceutical sciences. 104(2)
Sorbitol crystallization-induced aggregation of mAbs in the frozen state was evaluated. The effect of protein aggregation resulting from sorbitol crystallization was measured as a function of formulation variables such as protein concentration and pH
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8958665341836477e2aed65a2a93ed38
https://pubmed.ncbi.nlm.nih.gov/25219372
https://pubmed.ncbi.nlm.nih.gov/25219372
Autor:
Rohini Deshpande, Sheryl Martin-Moe, Y. John Wang, Susan Hershenson, Tim Osslund, Tahir A. Mahmood
Publikováno v:
Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals
The first synthetic drug, acetylsalicylate, produced in 1895 and patented as aspirin [1] (Bayer in 1900), marks the beginning of the modern pharmaceutical industry. Throughout the early to mid-1900s there was significant emphasis on development of sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e0eb89addd96b6c3609ca88cff0cfee
https://doi.org/10.1002/9780470595886.ch1
https://doi.org/10.1002/9780470595886.ch1
Autor:
Susan Hershenson, Feroz Jameel
Publikováno v:
Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals: Jameel/Manufacturing Biopharmaceuticals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0ef53a1e2a53b67a276f1bd54f88358
https://doi.org/10.1002/9780470595886
https://doi.org/10.1002/9780470595886
Autor:
Feroz Jameel, Susan Hershenson
A real-world guide to the production and manufacturing of biopharmaceuticals While much has been written about the science of biopharmaceuticals, there is a need for practical, up-to-date information on key issues at all stages of developing and manu